233 related articles for article (PubMed ID: 25017254)
1. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Gruber G; Greiner RH; Hlushchuk R; Aebersold DM; Altermatt HJ; Berclaz G; Djonov V
Breast Cancer Res; 2004; 6(3):R191-8. PubMed ID: 15084243
[TBL] [Abstract][Full Text] [Related]
3. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
4. Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer.
Dong M; Wan XB; Yuan ZY; Wei L; Fan XJ; Wang TT; Lv YC; Li X; Chen ZH; Chen J; Lin Q; Wen JY; Ma XK; Liu Q; Wu XY
Med Oncol; 2013 Mar; 30(1):355. PubMed ID: 23408367
[TBL] [Abstract][Full Text] [Related]
5. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients.
Dales JP; Garcia S; Meunier-Carpentier S; Andrac-Meyer L; Haddad O; Lavaut MN; Allasia C; Bonnier P; Charpin C
Int J Cancer; 2005 Sep; 116(5):734-9. PubMed ID: 15849727
[TBL] [Abstract][Full Text] [Related]
8. Expression of LPA2 is associated with poor prognosis in human breast cancer and regulates HIF-1α expression and breast cancer cell growth.
Li M; Xiao D; Zhang J; Qu H; Yang Y; Yan Y; Liu X; Wang J; Liu L; Wang J; Duan X
Oncol Rep; 2016 Dec; 36(6):3479-3487. PubMed ID: 27805252
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma.
Chai CY; Chen WT; Hung WC; Kang WY; Huang YC; Su YC; Yang CH
J Clin Pathol; 2008 May; 61(5):658-64. PubMed ID: 17908805
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer.
Zhang J; Wu Y; Lin YH; Guo S; Ning PF; Zheng ZC; Wang Y; Zhao Y
World J Gastroenterol; 2018 Jun; 24(22):2381-2391. PubMed ID: 29904245
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
13. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer.
Schoppmann SF; Fenzl A; Schindl M; Bachleitner-Hofmann T; Nagy K; Gnant M; Horvat R; Jakesz R; Birner P
Breast Cancer Res Treat; 2006 Sep; 99(2):135-41. PubMed ID: 16555123
[TBL] [Abstract][Full Text] [Related]
15. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
[TBL] [Abstract][Full Text] [Related]
16. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
[TBL] [Abstract][Full Text] [Related]
18. Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast.
Kuijper A; van der Groep P; van der Wall E; van Diest PJ
Breast Cancer Res; 2005; 7(5):R808-18. PubMed ID: 16168127
[TBL] [Abstract][Full Text] [Related]
19. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
[TBL] [Abstract][Full Text] [Related]
20. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]